Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

2.50
Hdl Handle:
http://hdl.handle.net/10029/621805
Title:
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
Authors:
Fregonese, Federica; Ahuja, Shama D; Akkerman, Onno W; Arakaki-Sanchez, Denise; Ayakaka, Irene; Baghaei, Parvaneh; Bang, Didi; Bastos, Mayara; Benedetti, Andrea; Bonnet, Maryline; Cattamanchi, Adithya; Cegielski, Peter; Chien, Jung-Yien; Cox, Helen; Dedicoat, Martin; Erkens, Connie; Escalante, Patricio; Falzon, Dennis; Garcia-Prats, Anthony J; Gegia, Medea; Gillespie, Stephen H; Glynn, Judith R; Goldberg, Stefan; Griffith, David; Jacobson, Karen R; Johnston, James C; Jones-López, Edward C; Khan, Awal; Koh, Won-Jung; Kritski, Afranio; Lan, Zhi Yi; Lee, Jae Ho; Li, Pei Zhi; Maciel, Ethel L; Galliez, Rafael Mello; Merle, Corinne S C; Munang, Melinda; Narendran, Gopalan; Nguyen, Viet Nhung; Nunn, Andrew; Ohkado, Akihiro; Park, Jong Sun; Phillips, Patrick P J; Ponnuraja, Chinnaiyan; Reves, Randall; Romanowski, Kamila; Seung, Kwonjune; Schaaf, H Simon; Skrahina, Alena; Soolingen, Dick van; Tabarsi, Payam; Trajman, Anete; Trieu, Lisa; Banurekha, Velayutham V; Viiklepp, Piret; Wang, Jann-Yuan; Yoshiyama, Takashi; Menzies, Dick
Abstract:
Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.
Citation:
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. 2018, 6 (4):265-275 Lancet Respir Med
Journal:
Lancet Respir Med 2018; 6(4):265-75
Issue Date:
Apr-2018
URI:
http://hdl.handle.net/10029/621805
DOI:
10.1016/S2213-2600(18)30078-X
PubMed ID:
29595509
Type:
Article
Language:
en
ISSN:
2213-2619
Appears in Collections:
Miscellaneous

Full metadata record

DC FieldValue Language
dc.contributor.authorFregonese, Federicaen
dc.contributor.authorAhuja, Shama Den
dc.contributor.authorAkkerman, Onno Wen
dc.contributor.authorArakaki-Sanchez, Deniseen
dc.contributor.authorAyakaka, Ireneen
dc.contributor.authorBaghaei, Parvanehen
dc.contributor.authorBang, Didien
dc.contributor.authorBastos, Mayaraen
dc.contributor.authorBenedetti, Andreaen
dc.contributor.authorBonnet, Marylineen
dc.contributor.authorCattamanchi, Adithyaen
dc.contributor.authorCegielski, Peteren
dc.contributor.authorChien, Jung-Yienen
dc.contributor.authorCox, Helenen
dc.contributor.authorDedicoat, Martinen
dc.contributor.authorErkens, Connieen
dc.contributor.authorEscalante, Patricioen
dc.contributor.authorFalzon, Dennisen
dc.contributor.authorGarcia-Prats, Anthony Jen
dc.contributor.authorGegia, Medeaen
dc.contributor.authorGillespie, Stephen Hen
dc.contributor.authorGlynn, Judith Ren
dc.contributor.authorGoldberg, Stefanen
dc.contributor.authorGriffith, Daviden
dc.contributor.authorJacobson, Karen Ren
dc.contributor.authorJohnston, James Cen
dc.contributor.authorJones-López, Edward Cen
dc.contributor.authorKhan, Awalen
dc.contributor.authorKoh, Won-Jungen
dc.contributor.authorKritski, Afranioen
dc.contributor.authorLan, Zhi Yien
dc.contributor.authorLee, Jae Hoen
dc.contributor.authorLi, Pei Zhien
dc.contributor.authorMaciel, Ethel Len
dc.contributor.authorGalliez, Rafael Melloen
dc.contributor.authorMerle, Corinne S Cen
dc.contributor.authorMunang, Melindaen
dc.contributor.authorNarendran, Gopalanen
dc.contributor.authorNguyen, Viet Nhungen
dc.contributor.authorNunn, Andrewen
dc.contributor.authorOhkado, Akihiroen
dc.contributor.authorPark, Jong Sunen
dc.contributor.authorPhillips, Patrick P Jen
dc.contributor.authorPonnuraja, Chinnaiyanen
dc.contributor.authorReves, Randallen
dc.contributor.authorRomanowski, Kamilaen
dc.contributor.authorSeung, Kwonjuneen
dc.contributor.authorSchaaf, H Simonen
dc.contributor.authorSkrahina, Alenaen
dc.contributor.authorSoolingen, Dick vanen
dc.contributor.authorTabarsi, Payamen
dc.contributor.authorTrajman, Aneteen
dc.contributor.authorTrieu, Lisaen
dc.contributor.authorBanurekha, Velayutham Ven
dc.contributor.authorViiklepp, Pireten
dc.contributor.authorWang, Jann-Yuanen
dc.contributor.authorYoshiyama, Takashien
dc.contributor.authorMenzies, Dicken
dc.date.accessioned2018-04-19T09:50:03Z-
dc.date.available2018-04-19T09:50:03Z-
dc.date.issued2018-04-
dc.identifier.citationComparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. 2018, 6 (4):265-275 Lancet Respir Meden
dc.identifier.issn2213-2619-
dc.identifier.pmid29595509-
dc.identifier.doi10.1016/S2213-2600(18)30078-X-
dc.identifier.urihttp://hdl.handle.net/10029/621805-
dc.description.abstractIsoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.en
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Respiratory medicineen
dc.titleComparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.en
dc.typeArticleen
dc.identifier.journalLancet Respir Med 2018; 6(4):265-75en

Related articles on PubMed

All Items in WARP are protected by copyright, with all rights reserved, unless otherwise indicated.